10月15日，诺华盘中上涨3.02%，报146.71美元，成交额1.25亿美元。
消息面上，公司此前披露美国FDA批准Rhapsido用于经H1抗组胺药控制不佳的成人症状性皮肤划痕症患者，属于其慢性皮肤病适应症扩展。
该药物被描述为首款针对症状性皮肤划痕症的治疗产品，反映诺华在免疫与皮肤疾病管线上的监管进展。相较此前多项临床受挫，此次获批有助于改善市场对其近期产品线执行力的预期。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
10月15日，诺华盘中上涨3.02%，报146.71美元，成交额1.25亿美元。
消息面上，公司此前披露美国FDA批准Rhapsido用于经H1抗组胺药控制不佳的成人症状性皮肤划痕症患者，属于其慢性皮肤病适应症扩展。
该药物被描述为首款针对症状性皮肤划痕症的治疗产品，反映诺华在免疫与皮肤疾病管线上的监管进展。相较此前多项临床受挫，此次获批有助于改善市场对其近期产品线执行力的预期。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.